Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.31
−$0.11 · -3.22%
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Latest quote
$3.31
−$0.11 · -3.22%
After-hours
$3.35
+$0.04 · +1.21%
Oct 9, 5:40 PM ET
Regular session · ET · Market data may be delayed.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Day range
Current $3.31
52-week range
Current $3.31
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
51
Fair Value
Sentiment
63
Bullish
Risk
60
Elevated Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Day range
Current $3.31
52-week range
Current $3.31
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 121.2M USD | 73.11M USD | 56.29M USD | — | — |
| Selling, general, and administrative | 24.62M USD | 7.76M USD | 8.49M USD | 3.52K USD | 43.36K USD |
| Operating expenses | 145.82M USD | 80.86M USD | 64.77M USD | 3.52K USD | 43.36K USD |
| Interest income | 11.34M USD | 6.38M USD | 72K USD | — | — |
| Depreciation and amortization | 610K USD | 208K USD | 92K USD | 3.52K USD | — |
| Operating income | −145.82M USD | −80.86M USD | −64.77M USD | −3.52K USD | −43.36K USD |
| Net income | −134.04M USD | −74.28M USD | −64.7M USD | −3.52K USD | −43.36K USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI12.52M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF4.91M0.01%95.4B USD0.05%$235+0.80%
State Street SPDR S&P Biotech ETFXBI2.34M0.02%10.11B USD0.35%$153.77+3.00%
iShares Biotechnology ETFIBB1.27M0.01%10.41B USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA779.84K0.00%21.73B USD0.03%$32.79+0.40%
Virtus Biotech Clinical Trials ETFBBC140.04K0.34%41M USD0.65%$44.1456+2.08%
Direxion Daily S&P Biotech Bull 3X SharesLABU107.9K0.02%597.13M USD0.96%$243.09+9.01%
Schwab U.S. Broad Market ETFSCHB94.34K0.00%45.06B USD0.03%$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVirtus Biotech Clinical Trials ETFBBCDirexion Daily S&P Biotech Bull 3X SharesLABUSchwab U.S. Broad Market ETFSCHBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.